Please ensure Javascript is enabled for purposes of website accessibility

Amarin Reports Q4 Results, Beats Earnings and Revenue Targets

By Mark Prvulovic – Feb 25, 2020 at 7:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sales from its fish-oil derivative drug are growing significantly.

Amarin (AMRN -0.92%) announced its fourth-quarter and full-year financial results on Tuesday afternoon. The company managed to beat both the revenue and earnings targets set by Wall Street analysts, thanks in no small part to sales of its fish-oil derived drug, Vascepa.

The pharmaceutical company reported $143.3 million in revenue for Q4 2019, an 85% increase from the $77.3 million reported in Q4 2018. Amarin just barely made a profit in this quarter, with $7.1 million in net income in comparison with the $33.7 net loss reported last year.

Several fish oil capsules in a wooden spoon on a desk.

Image source: Getty Images.

In addition, the company reaffirmed its 2020 guidance that expects net total revenue of somewhere between $650 million and $700 million for the year, with almost all of that coming from Vascepa sales. Wall Street was expecting an earnings-per-share (EPS) loss of $0.02, a figure that Amarin beat, reporting a positive $0.02 EPS. Amarin also beat analysts' expected $136 million revenue target quite handily.

Details about Vascepa

Vascepa is Amarin's only drug, having first received U.S. Food and Drug Administration (FDA) approval back in 2012 to lower triglyceride levels in patients. Back in December, the treatment also received expanded approval as a secondary therapy for patients with high triglyceride levels of 150 mg per deciliter or more.

"FDA approval of Vascepa represents the introduction of an important new treatment option for patients with severe hypertriglyceridemia," said Joseph Zakrzewski, Amarin's chairman and CEO. Vascepa had demonstrated strong clinical results in lowering levels of LDL cholesterol (the "bad" cholesterol) in patients.

Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
AMRN
$1.08 (-0.92%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.